Diamyd Medical

Diamyd Medical is a Swedish biotechnology company that develops precision medicine therapies for type one diabetes and LADA (Latent Autoimmune Diabetes in Adults). Its lead product candidate is Diamyd, an antigen-specific immunotherapy for preserving endogenous insulin production.

Diamyd is based on the therapeutic principle of antigen-specific immunomodulation using the recombinant human protein GAD (glutamic acid decarboxylase). It aims to reprogram the immune system to stop attacking and damaging the insulin-producing beta cells in the pancreas.

The company is currently conducting a confirmatory Phase three trial called DIAGNODE-3 evaluating Diamyd in 330 patients aged 12-28 recently diagnosed with type one diabetes who carry the HLA DR3-DQ2 gene. This gene marker is found in around 50% of type one diabetes patients.

Diamyd Medical is also developing Remygen, an investigational GABA-based therapy for regenerating and protecting beta cells. The company is setting up a manufacturing facility in Umea, Sweden to produce GAD65, the active ingredient in Diamyd.

Diamyd Medical’s shares are traded on Nasdaq Stockholm First North under the ticker symbol DMYD B.

Key customers and partnerships

Diamyd Medical partnered with medical research charity JDRF to support the DIAGNODE-3 trial by contributing USD 5 million in funding. The company aims to facilitate availability of Diamyd in the US following successful trial completion.

It also secured approval from regulatory bodies like the FDA for trial sites and conduct across European countries and the US.

Diamyd Medical actively collaborates with investigators at universities like Uppsala University in Sweden. The DIAGNODE-3 trial is coordinated by Linköping University and Norwegian University of Science and Technology (NTNU) is overseeing an investigator-initiated trial for LADA patients with Diamyd.